Locations:
Search IconSearch

No. 3 Medical Innovation for 2020: Inaugural Medication for Transthyretin Amyloid Cardiomyopathy

Tafamidis is first FDA-approved drug to treat potentially fatal disease

Until 2019, the sole treatment options for people with transthyretin amyloid cardiomyopathy were symptom management and, in some patients, heart transplant. That changed in May, when the FDA approved the small-molecule compound tafamidis for the treatment of this progressive and potentially fatal disease.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

According to results of the phase 3 ATTR-ACT study, tafamidis significantly reduced all-cause mortality at 30 months relative to placebo (30 percent vs. 43 percent) and resulted in fewer cardiovascular-related hospitalizations.

FDA approval of this breakthrough drug may be the first step in turning transthyretin amyloid cardiomyopathy from a life-threatening condition into a manageable chronic disease.

In this video, learn more about why tafamidis is one of Cleveland Clinic’s Top 10 Medical Innovations for 2020.

Inaugural Treatment for Transthyretin Amyloid Cardiomyopathy

“Heart failure and atrial fibrillation are two of the most common cardiac diagnoses of the elderly population. Though previously underdiagnosed, it is now clear that a condition called amyloidosis is an important cause of both of these conditions. When amyloidosis affects the heart, it is known as amyloid cardiomyopathy, a progressive and potentially fatal disease that results from destabilized transthyretin, a transport protein. It becomes misfolded and forms amyloid fibrils that deposit into the walls of the heart, stiffening the muscle, eventually leading to heart failure.



Until now, treatment for the condition has been limited to transplant. In May, an approval brought hope to these suffering individuals. Two drug formulations of the compound known as tafamidis have been dubbed the first ever treatment for the two subtypes of the condition, hereditary and wild type. Phase three clinical trial results showed a 30 percent reduced risk of death in patients receiving this breakthrough therapy.



The approval of a drug for these conditions effectively highlights the importance of providing a treatment option where there once was none.”

Advertisement

Related Articles

Photo of Tom Mihaljevic, MD, and Gary Cohn
A Fireside Chat about Digital Technology in Healthcare

Cleveland Clinic and IBM leaders share insights, concerns, optimism about impacts

23-CCC-4375920 Zipline drone delivery 650×450
Delivering Drugs via Drone

Cleveland Clinic will offer rapid, pinpoint airborne transport of medications and other medical items

SEM_Knipfer_3797162_Mentor Hospital Community Grand Opening_06-2
How Cleveland Clinic Is Greening Its Operating Rooms

Dedicated committee and surgical fellowship strive for sustainability, energy efficiency, waste reduction

22-CCC-2742016-Hero1-650×450
Top 10 Medical Innovations for 2022 Unveiled

Next-generation mRNA vaccines are among the advancements likely to change healthcare this year

22-CCC-2639874-CQD-Hero-650×450
Why Lead Safety Has Become Cleveland Clinic’s Top Priority for Community Health

$50 million pledge will help remove sources of lead exposure from Cleveland homes

Nurse conducts safety check on medications in hospital hallway
10 Leadership Mindsets for High Reliability Organizations

How to empower caregivers and engage patients in patient safety

mroz-spine-surgery-219
Thomas Mroz, MD, Named Chair of the Orthopaedic & Rheumatologic Institute

The spine surgeon will oversee more than 125 staff physicians in his new role

James Merlino, MD
James Merlino, MD, Named Inaugural Chief Clinical Transformation Officer

Merlino rejoins Cleveland Clinic to help execute bold strategic vision

Ad